CN102333455A - 包含菊苣酸和/或其衍生物的组合物 - Google Patents
包含菊苣酸和/或其衍生物的组合物 Download PDFInfo
- Publication number
- CN102333455A CN102333455A CN2010800055521A CN201080005552A CN102333455A CN 102333455 A CN102333455 A CN 102333455A CN 2010800055521 A CN2010800055521 A CN 2010800055521A CN 201080005552 A CN201080005552 A CN 201080005552A CN 102333455 A CN102333455 A CN 102333455A
- Authority
- CN
- China
- Prior art keywords
- acid
- composition
- cichoric
- derivative
- hydrolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 100
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 title claims abstract description 76
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 229930016920 cichoric acid Natural products 0.000 title claims abstract description 71
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 title claims abstract description 71
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 title abstract 3
- YDDGKXBLOXEEMN-PMACEKPBSA-N dicaffeoyl-D-tartaric acid Natural products O([C@H](C(=O)O)[C@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-PMACEKPBSA-N 0.000 title abstract 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 66
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims abstract description 53
- 241000894006 Bacteria Species 0.000 claims abstract description 37
- 239000004310 lactic acid Substances 0.000 claims abstract description 33
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 33
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 31
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 29
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000004883 caffeic acid Nutrition 0.000 claims abstract description 26
- 229940074360 caffeic acid Drugs 0.000 claims abstract description 26
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000013305 food Nutrition 0.000 claims abstract description 22
- 235000006193 cichoric acid Nutrition 0.000 claims description 72
- 230000007062 hydrolysis Effects 0.000 claims description 43
- 238000006460 hydrolysis reaction Methods 0.000 claims description 43
- 239000011975 tartaric acid Substances 0.000 claims description 27
- 235000013361 beverage Nutrition 0.000 claims description 16
- 241000186660 Lactobacillus Species 0.000 claims description 14
- 229940039696 lactobacillus Drugs 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 108010010102 chlorogenic acid esterase Proteins 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 241001608472 Bifidobacterium longum Species 0.000 claims description 7
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 235000013336 milk Nutrition 0.000 claims description 7
- 239000008267 milk Substances 0.000 claims description 7
- 210000004080 milk Anatomy 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 108090000371 Esterases Proteins 0.000 claims description 6
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 230000036542 oxidative stress Effects 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 244000298479 Cichorium intybus Species 0.000 claims description 4
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 4
- 240000006365 Vitis vinifera Species 0.000 claims description 4
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 4
- 230000009286 beneficial effect Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 240000008415 Lactuca sativa Species 0.000 claims description 2
- 235000003228 Lactuca sativa Nutrition 0.000 claims description 2
- 240000001949 Taraxacum officinale Species 0.000 claims description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 235000020795 whole food diet Nutrition 0.000 claims description 2
- 108010013043 Acetylesterase Proteins 0.000 claims 3
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 14
- 239000007788 liquid Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- SWGKAHCIOQPKFW-JTNORFRNSA-N Caftaric acid Chemical compound OC(=O)[C@H](O)[C@H](C(O)=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 SWGKAHCIOQPKFW-JTNORFRNSA-N 0.000 description 6
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 6
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 6
- SWGKAHCIOQPKFW-GHMZBOCLSA-N caffeoyltartaric acid Natural products OC(=O)[C@H](O)[C@H](C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 SWGKAHCIOQPKFW-GHMZBOCLSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- SWGKAHCIOQPKFW-UHFFFAOYSA-N trans-caffeoyl-tartaric acid Natural products OC(=O)C(O)C(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 SWGKAHCIOQPKFW-UHFFFAOYSA-N 0.000 description 6
- 235000013353 coffee beverage Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 3
- 235000016213 coffee Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- -1 glidant Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 108010038851 tannase Proteins 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 101001065065 Aspergillus awamori Feruloyl esterase A Proteins 0.000 description 2
- 241001480052 Aspergillus japonicus Species 0.000 description 2
- 240000006439 Aspergillus oryzae Species 0.000 description 2
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 102100037478 Glutathione S-transferase A2 Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008122 artificial sweetener Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000014438 salad dressings Nutrition 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102100031375 Endothelial lipase Human genes 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101000988800 Rattus norvegicus Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 235000015116 cappuccino Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- ORYOIBJWFDNIPD-UHFFFAOYSA-N diacetyl 2,3-dihydroxybutanedioate Chemical compound CC(=O)OC(=O)C(O)C(O)C(=O)OC(C)=O ORYOIBJWFDNIPD-UHFFFAOYSA-N 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000007983 food acid Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000013569 fruit product Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 108010092206 glutathione S-transferase alpha Proteins 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 235000015113 tomato pastes and purées Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/44—Polycarboxylic acids
- C12P7/46—Dicarboxylic acids having four or less carbon atoms, e.g. fumaric acid, maleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/0102—Tannase (3.1.1.20)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/151—Johnsonii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
本发明大体上涉及食品和饮料领域。特别地,例如提供了能够对受试者提供酒石酸和/或咖啡酸的组合物。本发明的一个实施方案是一种组合物,其包含含有菊苣酸和/或其衍生物的成分、和能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌。
Description
本发明大体上涉及食品和饮料领域。特别地,例如对受试者提供了能够提供酒石酸和/或咖啡酸的组合物。本发明的一个实施方案是一种组合物,其包含含有菊苣酸和/或其衍生物的成分、以及能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌。
研究显示咖啡酸(CA)具有缩小肿瘤的性能。CA的皮下和口服施用显著减少了肝转移。这些结果证实了CA的治疗潜力并提示CA的抗转移和抗肿瘤作用是通过MMP-9酶活性的选择性抑制和通过NF-κB和MMP-9催化活性的双重抑制进行转录下调来介导的。[Tae-Wook Chung,等人,FASEBJournal.2004;18:1670-1681]
已经知道咖啡酸衍生物咖啡酸苯乙酯(CAPE)具有抗有丝分裂、抗癌、抗炎症和免疫调节性能。[Natarajan等人,Proc Natl Acad Sci U S A.1996August 20;93(17):9090 9095]CAPE也抑制急性免疫和炎症反应。[Orban等人,NeuroImmunoModulation 2000;7:99-105]
研究也显示,当皮肤细胞暴露于紫外(UV)辐射,特别是UVC辐射[NERADIL,R.等人,Folia Biologica(Praha).2003;49:197-202]和UVB辐射[Stanifort等人,Carcinogenesis 2006 27(9):1803-1811]时,抗炎症和抗癌性能能够保护皮肤细胞。
已经知道酒石酸提供以下健康益处:其可增加粪便软化物,减少肠通过时间(Spiller等人,British Journal of Nutrition(2003),90,803-807),且可能是以酸碱态参与这些过程的(Sabboh等人,(2007),98,72-77)。
因此,希望提供具有咖啡酸和/或酒石酸的可用食品以产生上述益处。然而,简单的对食品补充咖啡酸和/或酒石酸是不理想的,因为这些化合物可能随时间而释放活性。
因此本发明的目的是制备可为受试者提供咖啡酸和/或酒石酸的食品,其可稳定贮存并且易于生产。
本发明者可通过提供食品组合物实现此目的,所述食品组合物允许从前体菊苣酸和/或其衍生物原位产生咖啡酸和/或酒石酸。
菊苣酸是
菊苣酸的衍生物包括
R1、R2、R3和/或R4可为相同的或可彼此不同。
在一个实施方案中,R1、R2、R3和/或R4可选自H;CH3;C1-C3烷基;芳基,例如苯基、苄基、甲苯基、邻位二甲苯基烷基;C1-C3酰基;氨基酸;单糖、二糖或寡糖。寡糖包含2至9个单糖单元。R1、R2、R3和R4可为相同的和/或可彼此不同。
菊苣酸的一个典型衍生物为例如以下化合物:
然后菊苣酸和/或其衍生物可被能够水解菊苣酸和/或其衍生物的乳酸细菌水解。此水解步骤将产生酒石酸和/或咖啡酸。
不希望受理论束缚,本发明者认为此水解如以下图所示发生。注意,所有由“酶”催化的反应步骤也可由本申请中描述的乳酸细菌和/或由乳酸细菌和酶的组合催化。
本发明者惊讶地发现用能够水解菊苣酸和/或其衍生物的乳酸细菌处理包含菊苣酸和/或其衍生物的成分,以产生酒石酸和/或咖啡酸导致例如所述成分的抗氧化性和/或抗炎症性能的改进。
此外,发现当人或动物摄取了包含菊苣酸和/或其衍生物和能够水解绿原酸以产生酚酸的乳酸细菌组合的组合物后,此处理可在体内进行。
由此本发明的一个实施方案是一种组合物,其包含含有菊苣酸和/或其衍生物的成分、和能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌。
本发明的组合物可优选地作为食品、食品补充剂或饮料用于口服施用,或用于胃肠外应用。
在优选的实施方案中所述成分富含菊苣酸和/或其衍生物。例如,所述成分和/或所述组合物可包含以下范围的量的菊苣酸和/或其衍生物,0.001-99.99重量%的干重,优选0.1-50重量%的干重,最优选0.1-10重量%的干重。所述成分和/或所述组合物可包含以下范围的量的能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌,0.001-99.99重量%的干重,优选0.1-50重量%的干重,最优选0.1-10重量%的干重。
例如本发明的组合物可包含一种含有菊苣酸和/或其衍生物的成分、和另一种含有能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌的成分。
含有菊苣酸和/或其衍生物的成分可为天然或以添加的形式含有菊苣酸和/或其衍生物的任意成分,但优选天然食品例如莴苣、菊苣、蒲公英、葡萄、葡萄果渣;或其组合或提取物。
待与含有菊苣酸和/或其衍生物的成分混合的成分包含乳酸细菌,其能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸。这两种成分可在食用前不久混合或可作为可立即食用的组合物提供。
优选的能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌是具有酯酶活性,例如绿原酸酯酶和/或阿魏酸酯酶的益生乳酸细菌,优选乳杆菌或双歧杆菌,例如约氏乳杆菌(L.Johnsonii)、长双歧杆菌(B.Longum)和乳双歧杆菌(B.Lactis)(CNCM I-3446),更优选约氏乳杆菌La1(CNCM I-1225)、长双歧杆菌BB 536和乳双歧杆菌BB12。
长双歧杆菌BB 536可购自Morinaga Nutritional Foods,Inc.。
乳双歧杆菌BB12可购自例如Chr.Hansen,DK-2970 Horsholm。
在本发明的一个实施方案中,乳酸细菌可以非复制形式使用。
可如实施例2、3和/或4中对约氏乳杆菌(La1)的详细描述检测乳酸细菌或其部分水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的能力。
在消化的时侯乳酸细菌应当以足够水解大部分菊苣酸以产生酒石酸和/或咖啡酸的量存在。需要的乳酸细菌和/或酶的量可例如由本领域技术人员测定,例如取决于待治疗的受试者或酒石酸和/或咖啡酸应当释放的速度。在组合物中存在的优选至少5%,例如至少30%,至少50%或至少75%的菊苣酸在食用前和/或食用时已被水解。
在另一个实施方案中,对乳酸细菌进一步加入能够水解菊苣酸以产生酒石酸和/或咖啡酸的酶。优选地,这样的酶选自酯酶,例如绿原酸酯酶、鞣酸酶和/或阿魏酸酯酶。以使例如在组合物中存在的优选至少5%,例如至少30%,至少50%或至少75%的菊苣酸在食用前和/或食用时已被水解的量加入所述酶。
在本发明的框架中可使用的合适的酶包括例如酯酶,例如来源于日本曲霉(Aspergillus japonicus)的绿原酸酯酶(可购自Kikkoman,Japan),来自米曲霉(Aspergillus oryzae)的鞣酸酶(EC 3.1.1.20)(可购自Kikkoman,Japan)和Palatase 20000L(EC 3.1.1.3)(可购自NovozymesA/S,Denmark)。酶可以纯化的酶或微生物的细胞裂解物的形式存在。合适的细胞可为例如上面提到的微生物的细胞。产生细胞裂解物的合适方法是本领域已知的。
应当将本发明的组合物和/或成分配制为使乳酸细菌菌株在贮存期间不会发酵或不与组合物反应。这可通过例如将组合物配制为干粉和/或通过封装乳酸细菌使其仅在所述组合物与至少一种其他成分混合时或在消化时被释放而实现。
本发明的组合物可为营养完全配方,乳制品,冷冻的或耐贮存饮料,用于授乳母亲的产品,液体饮料,汤,饮食补充剂,膳食替代物,营养棒,糕点糖果(confectionery),乳制品或发酵乳制品,酸奶,基于奶的粉末,肠内营养产品,婴儿配方,婴儿营养产品,浓汤(puree),谷类制品或发酵的基于谷类的产品,冰淇淋,糖果,甜食,饼干,蛋糕,巧克力,热牛奶咖啡,咖啡,烹饪产品例如蛋黄酱、番茄酱(tomato puree)或色拉酱,宠物食品或宠物饮料。
如果产品是用于口服施用的营养补充剂,其可存在于胶囊、明胶胶囊、软胶囊、片剂、糖衣片剂、丸剂、糊剂或糖果锭剂、口香糖或可饮用溶液或乳剂、糖浆或凝胶。这样的补充剂可能也包括甜味剂、稳定剂、抗氧化剂、添加剂、调味剂和/或着色剂。
每种成分可包含任意类型的可食用化合物。用于食品组合物特别是饮料的一般成分是本领域熟知的,例如奶、奶油、咖啡增白剂和咖啡奶精。可选地,成分也可为例如色拉酱或其部分。这些化合物可被消费者用于修饰例如组合物的香味、外观和质地。成分可为液体或干燥形式,例如作为在饮料中溶解和/或悬浮的粉末。
本发明的组合物可进一步包含适于在食品组合物中包含的其他成分。通常成分可为例如糖、人工甜味剂、乳化剂、稳定剂、增稠剂、助流剂、色素、调料、芳香剂等等。合适的人工甜味剂包括糖精、甜蜜素、acetosulfame、基于L-天冬胺酰基的甜味剂例如阿斯巴甜和这些甜味剂的混合物。合适的乳化剂包括单甘酯、双甘酯、卵磷脂、单-双甘酯的二乙酰酒石酸酯、乳化淀粉及其混合物。合适的稳定剂包括磷酸氢二钾和柠檬酸钠。合适的助流剂为sodium silica aluminate。在一个实施方案中组合物包含乳蛋白和/或植物蛋白。在另一个实施方案中组合物包含乳脂和/或植物脂肪。
本发明的组合物可包含蛋白质源,碳水化合物源和/或脂源。如果组合物计划用作全餐或用作膳食替代物,则优选包含蛋白质源、碳水化合物源和脂源,从而满足待治疗的受试者的营养需要。
例如蛋白质源可包含乳蛋白和/或植物蛋白,脂源可包含乳脂和/或植物脂肪,和/或碳水化合物源可包含奶和/或植物碳水化合物以保证最佳营养价值。
此外,组合物可包含适于口服或肠内施用的有机或无机载体材料以及维生素、矿物质微量元素和其他微量营养素,例如依照政府部门例如USRDA的推荐。
在一个实施方案中本发明涉及包含下述的饮料粉末:a)包含菊苣酸和/或衍生物提取物的干燥水溶性组合物;和b)能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌。
根据本发明的饮料粉末是用于制备饮料的粉末,通过在液体例如水或奶中溶解或悬浮所述粉末制备饮料。
本发明的产品可用于提高食用例如从本发明的产品制备的饮料的人或动物体内的抗氧化能力,例如通过增强Nrf2介导的基因表达途径,即诱导解毒酶例如谷胱甘肽-S-转移酶(GST)。据报道,Nrf2相关基因的活性提高可增强解毒作用和刺激针对氧化应激的内源防御。
本发明的组合物可用于例如减轻炎症,例如通过降低前列腺素E2水平。
许多健康问题和疾病,特别是衰老相关疾病与氧化应激和炎症有关。本发明的产品可用于治疗或预防食用从本发明的产品制备的饮料的人或动物中的这些问题或疾病。相关问题和疾病是例如脑疾病;炎症;肥胖;和癌症。
本发明的组合物可进一步用作抗糖尿病剂,例如通过降低血糖水平,和/或提高瘦素、胰岛素和/或c-肽的血液水平;作用骨重塑剂,例如通过提高骨矿物质密度,例如通过提高雌性激素和/或黄体酮的血清水平和/或提高碱性磷酸酶活性;作为抗转移剂,例如通过抗血管生成作用。
因此,本发明的一个实施方案是如此处描述的组合物在制备组合物中的用途,所述组合物用于治疗或预防炎症疾病,特别是与细菌和/或病毒感染相关联的炎症疾病;用于增强人或动物的抗氧化能力;用于治疗或预防氧化应激相关疾病;用于治疗或预防代谢疾病,例如糖尿病;用于治疗或预防与骨矿物质密度相关的疾病;或用于治疗或预防癌症。
在一个实施方案中本发明涉及用于制备食品例如饮料的试剂盒,其包含至少2个部分:a)包含含有菊苣酸和/或其衍生物的食品成分的第一部分;和b)包含能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌的第二部分。两部分可一起出售以制备食品例如饮料,但可在产品包装中是物理上分离的。通过在食用前不久混合两部分可制备待食用的最终食品。如果1个或2个部分是液体形式,它们可直接混合,可选地进一步加入其他液体,例如水或奶。也可通过将它们溶解或悬浮在液体例如水或奶中混合两部分。当使用液体时,其可为热的或冷的。如果使用热的液体,其可优选地具有不过高的温度以免在消化食品、食品补充剂或饮料前失活乳酸细菌和酶(如果有的话)。
试剂盒的第一部分可包含含有菊苣酸和/或其衍生物的食品或提取物。在优选的实施方案中,第一部分是干燥的形式,例如粉末的形式。第一部分也可为液体形式。第一部分可另外包含任意其他合适的成分,例如香味添加剂、稳定剂、盐和/或甜味剂。可以任意合适的方式包装第一部分,例如在小袋、瓶或罐中。
第二部分包含能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌。此部分可优选的为与第一部分混合的组合物的形式。其可为干燥的形式,例如粉末,或为液体形式,并可以任意合适的方式包装,例如在小袋、瓶或罐中。其应当配制为使乳酸细菌在贮存期间不会发酵或与其他成分反应。这可通过例如将组合物配制成干粉和/或通过封装乳酸细菌达到。
可以任意合适的方式将至少2个部分包装在一起。它们可例如在组合的容器中包装,其中各部分在贮存期间物理地分离但当容器被打开时混合,或它们可在分别的容器中包装,其在一起出售以制备食品、食品补充剂或饮料。
本领域技术人员将理解他们可自由组合此处描述的本发明的所有特征而不背离公开的本发明的范围。特别地,对于本发明的用途所描述的特征可应用于本发明的组合物和/或试剂盒,反之亦然。
通过以下实施例和图,本发明的其他优势和特征显而易见。
图1显示了菊苣酸(◆)至咖啡酸(▲)和咖啡酰酒石酸(●)的水解,使用绿原酸酯酶。
图2显示了菊苣酸(◆)至咖啡酸(▲)和咖啡酰酒石酸(■)的水解,使用约氏乳杆菌的喷雾干燥制剂。
图3显示了用菊苣酸处理AREc报告细胞系的结果。
图4显示了用被La1水解的菊苣酸处理AREc报告细胞系的结果:(■)50%水解,(□)100%水解
实施例:
1-使用绿原酸酯酶的菊苣酸的水解
将在100μl磷酸缓冲液(50mM,pH7.0)中的绿原酸酯酶(0.8mg,24U/g,来自Kikkoman Japan)溶液加入在100μl磷酸缓冲液(50mM,pH7.0)中的菊苣酸(0.57mg)溶液。然后将混合物在37℃孵育4小时。在反应时间后,通过热处理(5分钟,90℃)终止酶活性并离心(microcon YM10,30分钟,14000g)混合物。然后通过HPLC分析上清。在相同反应条件下平行进行反应对照,但不含酶。
2-使用约氏乳杆菌(La1)新鲜细胞的菊苣酸的水解
培养(7.0 E08 cfu/ml)和离心(5000g,10分钟)约氏乳杆菌(CNCMI-1225)细胞,在磷酸缓冲液(50mM,pH7.0)中将沉淀重悬为0.61g/ml的浓度。对100μl此细胞溶液加入100μl菊苣酸溶液(12mM)并将混合物在37℃孵育。在不同反应时间取样,离心(3000g,5分钟)并过滤通过0.45μm孔径的注射滤器(Millipore SLHA 025 BS),然后通过HPLC分析。
在相同反应条件下平行进行反应对照,但不含细菌。
3-使用约氏乳杆菌提取物(裂解细胞)的菊苣酸的水解
培养(7.0 E08 cfu/ml)和离心(5000g,10分钟)约氏乳杆菌(CNCMI-1225)细胞,在磷酸缓冲液(50mM,pH7.0)中将沉淀重悬为0.61g/ml的浓度。然后使用玻璃珠方法裂解细胞。将600μl细胞制剂放进Mini-Beadbeater,强烈摇晃1分钟,在冰上冷却,然后放进Mini-Beadbeater再强烈摇晃1分钟。然后将粗细胞提取物(100μl)加入100μl菊苣酸溶液(12mM,磷酸缓冲液50mM,pH7.0)并将混合物在37℃孵育。在不同反应时间取样,离心(3000g,5分钟)并过滤通过0.45μm孔径的注射滤器(Millipore SLHA 025 BS),然后通过HPLC分析。
4-使用La1的喷雾干燥制剂的菊苣酸的水解
将10mg La1的喷雾干燥制剂(3.3 E09 cfu/g)在100μl磷酸缓冲液(50mM,pH7.0)中溶解。对此溶液加入100μl菊苣酸溶液(12mM,磷酸缓冲液50mM,pH7.0)。然后将混合物在37℃孵育并在不同反应时间取样。离心(3000g,5分钟)和过滤(0.45μm孔径的注射滤器,Millipore SLHA025 BS)后通过HPLC分析样品。
HPLC分析
在装备有Atlantis C18反相柱(4.6x100mm,颗粒大小3μm)和二极管矩阵检测器的Agilent 1100系统上进行菊苣酸和水解产物的HPLC-DAD分析。用含有0.1%甲酸的水平衡柱。注射后,在12分钟内以1ml/分钟的流速运行线性梯度至55%水和45%乙腈(含0.1%甲酸)的最终溶剂组成。通过320nm处的UV监测菊苣酸和咖啡酸并使用标准校准曲线定量。
5-体外检测
抗氧化应答元件(ARE)荧光素酶测定
将含有在大鼠谷胱甘肽-S-转移酶A2(GSTA2)中的8个ARE拷贝的pGL-8xARE和含有新霉素选择标记的pcDNA3.1质粒稳定转染至人MCF7细胞(Wang等人,Cancer Res.66,10983-10994,2006)。ARE(抗氧化应答元件)是转录因子Nrf2的结合位点,Nrf2调节参与解毒和针对氧化应激的内源防御的基因。质粒pGL-8xARE在8个Nrf2结合位点下游包含使得能够监测Nrf2活性的荧光素酶基因。为了用菊苣酸和相关化合物处理,将AREc 32细胞在DMEM生长培养基中接种在96孔微滴定板上。用不同的制剂处理24小时后,测定萤火虫荧光素酶活性。
结果
检测的细菌
约氏乳杆菌(La1)、长双歧杆菌BB 536和乳双歧杆菌BB12特别能够水解菊苣酸。使用约氏乳杆菌(La1)得到反应速率和反应产量方面的最佳结果。
检测的酶
只有绿原酸和阿魏酸酯酶能够将菊苣酸水解为咖啡酸和酒石酸。
1-使用绿原酸酯酶的菊苣酸的水解
表1:通过绿原酸酯酶将菊苣酸水解为咖啡酸和咖啡酰酒石酸。浓度以t=0时相对未处理参考的%表示。
时间(分钟) | 0 | 15 | 30 | 60 | 120 | 240 |
菊苣酸 | 98 | 85 | 83 | 77 | 65 | 50 |
咖啡酰酒石酸 | 0 | 6 | 7 | 10 | 16 | 24 |
咖啡酸 | 2 | 9 | 10 | 13 | 19 | 26 |
2-使用La1新鲜细胞的菊苣酸的水解
通过HPLC分析,在4小时反应时间后所有菊苣酸转化为咖啡酸。
3-使用La1提取物(裂解细胞)的菊苣酸的水解
与全细胞相比,使用裂解细胞水解菊苣酸导致提高的反应速率。事实上,仅2小时后所有菊苣酸就转化为咖啡酸。
4-使用La1的喷雾干燥制剂的菊苣酸的水解
表2:通过约氏乳杆菌的喷雾干燥制剂将菊苣酸水解为咖啡酸和咖啡酰酒石酸。浓度以相对t=0时未处理参考的%表示。
0分钟 | 15分钟 | 30分钟 | 1小时 | 2小时 | 3小时 | |
菊苣酸(毫摩尔) | 365 | 172 | 137 | 91 | 49 | 23 |
咖啡酰酒石酸(毫摩尔) | 0 | 62 | 63 | 50 | 31 | 15 |
咖啡酸(毫摩尔) | 0 | 324 | 393 | 498 | 601 | 669 |
5-体外检测:
抗氧化应答元件(ARE)荧光素酶测定
使用由若干拷贝的大鼠GSTA2-ARE报告构建体稳定转染的人乳腺癌细胞(AREc32)证明菊苣酸和相关化合物对Nrf2-ARE途径的激活。未水解的菊苣酸和用La1水解的菊苣酸(50%和100%)产生了Nrf2-荧光素酶报告活性的正向剂量依赖性应答(见表3,4)并展示了在较高剂量下的饱和失活应答。
表3:用菊苣酸处理的AREc报告细胞系
μg/ml | F/C | stdv |
100 | 2580 | 592 |
200 | 4364 | 876 |
400 | 8810 | 492 |
600 | 558 | 105 |
800 | 251 | 166 |
1000 | 346 | 214 |
表4:用La1水解的菊苣酸处理的AREc报告细胞系:(A)50%水解,(B)100%水解
μg/ml | F/C A | F/C B | Stdv-A | Stdv-B |
50 | 3584 | 3924 | 934 | 2070 |
75 | 3732 | 6157 | 812 | 3811 |
100 | 7230 | 14579 | 1141 | 9995 |
125 | 9797 | 24309 | 5387 | 12053 |
150 | 12208 | 16900 | 332 | 3903 |
200 | 764 | 4652 | 987 | 7151 |
PCT/RO/134表
Claims (15)
1.组合物,其包含含有菊苣酸和/或其衍生物的成分、和能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌。
2.权利要求1的组合物,其进一步包含蛋白质来源、碳水化合物来源和/或脂来源。
3.权利要求2的组合物,其中所述蛋白质来源包含乳蛋白和/或植物蛋白,所述脂来源包含乳脂和/或植物脂肪,和/或所述碳水化合物来源包含奶和/或植物的碳水化合物。
4.权利要求1-3中任一项的组合物,其中所述组合物为食品,食品补充剂或饮料,或用于胃肠外应用的组合物。
5.权利要求1-3中任一项的组合物,其中所述组合物为粉末形式。
6.权利要求1-5中任一项的组合物,其中所述能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌是具有酯酶活性,例如绿原酸酯酶和/或阿魏酸酯酶活性的益生乳酸细菌。
7.权利要求1-6中任一项的组合物,其中所述乳酸细菌选自约氏乳杆菌、长双歧杆菌和乳双歧杆菌,特别是约氏乳杆菌(CNCM I-1225)、长双歧杆菌BB 536、乳双歧杆菌(CNCM I-3446)和乳双歧杆菌BB12。
8.权利要求1-7中任一项的组合物,其中所述包含菊苣酸的成分为天然食品例如莴苣、菊苣、蒲公英、葡萄、葡萄果渣;或其组合或提取物。
9.权利要求1-8中任一项的组合物,其进一步包含能够水解菊苣酸以产生酒石酸和/或咖啡酸的酶。
10.权利要求1-9中任一项的组合物在制备这样的组合物中的用途,该组合物用于治疗或预防炎症疾病,特别是与细菌和/或病毒感染相联系的炎症疾病;用于增强人或动物的抗氧化能力;用于治疗或预防氧化应激相关疾病;用于治疗或预防代谢疾病,例如糖尿病;用于治疗或预防与骨矿物质密度相关的疾病;和/或用于治疗或预防癌症。
11.乳酸细菌在含有菊苣酸和/或其衍生物的组合物中的用途,所述乳酸细菌能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸。
12.权利要求11的用途,其中所述能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌是具有酯酶活性,例如绿原酸酯酶和/或阿魏酸酯酶活性的益生乳酸细菌。
13.权利要求10-12中的任一项的用途,其中所述组合物是根据权利要求1-7中任一项的食品组合物。
14.用于制备食品或食品补充剂或饮料的试剂盒,其包含至少2个部分:
a)包含含有菊苣酸和/或其衍生物的食品成分的第一部分;和
b)包含能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌的第二部分。
15.权利要求14的试剂盒,其中所述能够水解菊苣酸和/或其衍生物以产生酒石酸和/或咖啡酸的乳酸细菌是具有酯酶活性,例如绿原酸酯酶和/或阿魏酸酯酶活性的益生乳酸细菌。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09151390.3 | 2009-01-27 | ||
EP09151390A EP2210504A1 (en) | 2009-01-27 | 2009-01-27 | Composition comprising chicoric acid and/or derivatives thereof |
PCT/EP2010/050914 WO2010086322A1 (en) | 2009-01-27 | 2010-01-27 | Composition comprising chicoric acid and/or derivatives thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102333455A true CN102333455A (zh) | 2012-01-25 |
Family
ID=40635768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800055521A Pending CN102333455A (zh) | 2009-01-27 | 2010-01-27 | 包含菊苣酸和/或其衍生物的组合物 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20110280848A1 (zh) |
EP (2) | EP2210504A1 (zh) |
JP (1) | JP2012515541A (zh) |
KR (1) | KR20110119723A (zh) |
CN (1) | CN102333455A (zh) |
AR (1) | AR075188A1 (zh) |
AU (1) | AU2010209797A1 (zh) |
BR (1) | BRPI1007194A2 (zh) |
CA (1) | CA2750685A1 (zh) |
CO (1) | CO6400174A2 (zh) |
MX (1) | MX2011007471A (zh) |
RU (1) | RU2011135819A (zh) |
WO (1) | WO2010086322A1 (zh) |
ZA (1) | ZA201106300B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102958501A (zh) * | 2010-06-30 | 2013-03-06 | 雀巢产品技术援助有限公司 | 菊苣酸及衍生物用于调节皮肤色素沉着的用途 |
CN103025309A (zh) * | 2010-06-30 | 2013-04-03 | 雀巢产品技术援助有限公司 | 菊苣酸和乳酸菌在食品补充剂中用于调节皮肤色素沉着的用途 |
CN103408423A (zh) * | 2013-07-17 | 2013-11-27 | 张家港威胜生物医药有限公司 | 一种天然活性产物l-菊苣酸的合成工艺 |
CN108603162A (zh) * | 2015-09-15 | 2018-09-28 | 庆熙大学校产学协力团 | 预防、改善或治疗退行性脑病或认知功能障碍的新型乳酸菌和组合物 |
CN111885996A (zh) * | 2018-03-23 | 2020-11-03 | 森永乳业株式会社 | 臭味成分失活用组合物 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1917960A1 (en) * | 2006-11-06 | 2008-05-07 | Nestec S.A. | Improved biological effects of rosmarinic acid |
SG186804A1 (en) * | 2010-06-30 | 2013-02-28 | Nestec Sa | Use of caftaric acid and derivatives in food supplement for regulating skin pigmentation |
ES2754050T3 (es) * | 2011-10-11 | 2020-04-15 | Elc Man Llc | Método y composiciones para tratar la piel |
EP2863929B1 (en) | 2012-06-22 | 2016-07-20 | Nestec S.A. | Probiotic and polyphenol against neurodegeneration |
KR20230017357A (ko) * | 2013-03-12 | 2023-02-03 | 에이치엠아이 메디칼 이노베이션즈, 엘엘씨 | 항당뇨병성 및 다른 유용한 활성을 갖는 식물 추출물 |
CN110786241B (zh) * | 2019-11-28 | 2022-03-22 | 大连市现代农业生产发展服务中心(大连市农业科学研究院) | 一种提高液体培养紫锥菊不定根中菊苣酸积累的培养方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU459273B2 (en) * | 1971-05-17 | 1975-03-20 | Sankyo Company Limited | Process for making wines |
FR2591073B1 (fr) * | 1985-12-10 | 1988-02-19 | Leroux Sarl Chicoree | Boisson a base de chicoree et procede de preparation de ladite boisson |
JP2003250528A (ja) * | 2002-03-06 | 2003-09-09 | Yakult Honsha Co Ltd | ビフィドバクテリウム属細菌の生残性改善剤、増殖促進剤、又は、同細菌含有醗酵物の製造方法 |
US20040001898A1 (en) * | 2002-06-26 | 2004-01-01 | Armand Malnoe | Compositions and methods for detoxification and cancer prevention |
EP2289348A3 (en) * | 2003-03-25 | 2011-03-23 | Aarhus Universitet | Methodologies for improving the quality of meat, health status of animals and impact on environment |
SE527555C2 (sv) * | 2003-04-04 | 2006-04-11 | Probi Ab | Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar |
CA2882532C (en) * | 2004-09-01 | 2016-06-07 | Victor Nsereko | Ferulate esterase producing strain lactobacillus crispatus li2350 and methods of using same as a silage inoculant |
ES2520017T3 (es) * | 2005-09-28 | 2014-11-11 | The Regents Of The University Of California | Procedimiento de reducción de la presión sanguínea en individuos prehipertensos y/o individuos con síndrome metabólico |
ES2542713T3 (es) * | 2005-09-28 | 2015-08-10 | Constellation Brands, Inc. | Extracto de uva, suplemento en la dieta del mismo y procedimiento de preparación |
FR2904935A1 (fr) * | 2006-08-18 | 2008-02-22 | Centre Nat Rech Scient | Composition antidiabetique apte a stimuler la secretion d'insuline et destinee au traitement du diabete de type 2 (diabete non insulino-dependant). |
EP2061483A1 (en) * | 2006-09-07 | 2009-05-27 | McGill University | Oral polymeric membrane feruloyl esterase producing bacteria formulation |
EP1917960A1 (en) * | 2006-11-06 | 2008-05-07 | Nestec S.A. | Improved biological effects of rosmarinic acid |
EP1932517A3 (en) * | 2006-12-11 | 2008-07-16 | Universiteit Utrecht Holding B.V. | Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof |
WO2008093670A1 (ja) * | 2007-02-01 | 2008-08-07 | Tk Bio-Research Laboratory Co., Ltd. | ブドウ果皮・種子乳酸菌発酵物、並びにそれを利用した医薬及び食品 |
EP1985191A1 (en) * | 2007-04-27 | 2008-10-29 | Universita'degli Studi Di Milano | Preparation of polyfunctional fermented food products |
RU2513688C2 (ru) * | 2008-04-30 | 2014-04-20 | Нестек С.А. | Композиции для приготовления напитка |
WO2009155689A1 (en) * | 2008-06-24 | 2009-12-30 | Micropharma Limited | Nitric oxide device and method for wound healing, treatment of dermatological disorders and microbial infections |
-
2009
- 2009-01-27 EP EP09151390A patent/EP2210504A1/en not_active Withdrawn
-
2010
- 2010-01-27 RU RU2011135819/13A patent/RU2011135819A/ru not_active Application Discontinuation
- 2010-01-27 CN CN2010800055521A patent/CN102333455A/zh active Pending
- 2010-01-27 CA CA2750685A patent/CA2750685A1/en not_active Abandoned
- 2010-01-27 MX MX2011007471A patent/MX2011007471A/es not_active Application Discontinuation
- 2010-01-27 EP EP10702095A patent/EP2391228A1/en not_active Withdrawn
- 2010-01-27 AU AU2010209797A patent/AU2010209797A1/en not_active Abandoned
- 2010-01-27 KR KR1020117019447A patent/KR20110119723A/ko not_active Application Discontinuation
- 2010-01-27 JP JP2011546828A patent/JP2012515541A/ja active Pending
- 2010-01-27 US US13/145,656 patent/US20110280848A1/en not_active Abandoned
- 2010-01-27 WO PCT/EP2010/050914 patent/WO2010086322A1/en active Application Filing
- 2010-01-27 BR BRPI1007194-6A patent/BRPI1007194A2/pt not_active IP Right Cessation
- 2010-01-27 AR ARP100100204A patent/AR075188A1/es not_active Application Discontinuation
-
2011
- 2011-07-13 CO CO11087834A patent/CO6400174A2/es active IP Right Grant
- 2011-08-26 ZA ZA2011/06300A patent/ZA201106300B/en unknown
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102958501A (zh) * | 2010-06-30 | 2013-03-06 | 雀巢产品技术援助有限公司 | 菊苣酸及衍生物用于调节皮肤色素沉着的用途 |
CN103025309A (zh) * | 2010-06-30 | 2013-04-03 | 雀巢产品技术援助有限公司 | 菊苣酸和乳酸菌在食品补充剂中用于调节皮肤色素沉着的用途 |
CN103025307A (zh) * | 2010-06-30 | 2013-04-03 | 雀巢产品技术援助有限公司 | 菊苣酸及衍生物用于调节皮肤色素沉着的用途 |
CN103025309B (zh) * | 2010-06-30 | 2016-04-06 | 雀巢产品技术援助有限公司 | 菊苣酸和乳酸菌在食品补充剂中用于调节皮肤色素沉着的用途 |
CN102958501B (zh) * | 2010-06-30 | 2016-10-26 | 雀巢产品技术援助有限公司 | 菊苣酸及衍生物用于调节皮肤色素沉着的用途 |
CN103408423A (zh) * | 2013-07-17 | 2013-11-27 | 张家港威胜生物医药有限公司 | 一种天然活性产物l-菊苣酸的合成工艺 |
CN108603162A (zh) * | 2015-09-15 | 2018-09-28 | 庆熙大学校产学协力团 | 预防、改善或治疗退行性脑病或认知功能障碍的新型乳酸菌和组合物 |
CN111885996A (zh) * | 2018-03-23 | 2020-11-03 | 森永乳业株式会社 | 臭味成分失活用组合物 |
Also Published As
Publication number | Publication date |
---|---|
ZA201106300B (en) | 2013-02-27 |
MX2011007471A (es) | 2011-08-03 |
AU2010209797A1 (en) | 2011-07-28 |
US20110280848A1 (en) | 2011-11-17 |
BRPI1007194A2 (pt) | 2015-08-25 |
JP2012515541A (ja) | 2012-07-12 |
CA2750685A1 (en) | 2010-08-05 |
KR20110119723A (ko) | 2011-11-02 |
EP2210504A1 (en) | 2010-07-28 |
CO6400174A2 (es) | 2012-03-15 |
RU2011135819A (ru) | 2013-03-10 |
AR075188A1 (es) | 2011-03-16 |
WO2010086322A1 (en) | 2010-08-05 |
EP2391228A1 (en) | 2011-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102333455A (zh) | 包含菊苣酸和/或其衍生物的组合物 | |
CN102333459A (zh) | 包含咖啡酰酒石酸和/或其衍生物的组合物 | |
JP5923238B2 (ja) | 迷走神経活性化剤 | |
US20210139842A1 (en) | Novel bifidobacterium bacteria and composition including novel bifidobacterium bacteria | |
JP5888701B2 (ja) | 高タンパク質分解活性を有するラクトバチルス・ヘルベティカス菌 | |
JP2019528763A (ja) | 新規なラクトバチルス・サケイ及びそれを含む組成物 | |
US20210244777A1 (en) | Novel bifidobacterium bacteria and composition including novel bifidobacterium bacteria | |
JP7041508B2 (ja) | 概日リズム改善用組成物 | |
TW201034584A (en) | Process for producing γ-aminobutyric acid-rich material | |
TW201630596A (zh) | 鞘脂質吸收促進劑 | |
JP5950993B2 (ja) | 迷走神経活性化剤 | |
KR102523775B1 (ko) | 단백질 분해능을 가지는 락토바실러스 플란타럼 idcc 3501을 포함하는 식품 조성물 및 건강기능식품 | |
KR102538090B1 (ko) | 단백질 분해능을 가지는 락토바실러스 카제이 idcc 3451을 포함하는 식품 조성물 및 건강기능식품 | |
EP3479836B1 (en) | Cartilage regeneration facilitating composition | |
KR102423025B1 (ko) | 단백질 분해능을 가지는 락토바실러스 람노서스 idcc 3201을 포함하는 식품 조성물 및 건강기능식품 | |
JP2006182654A (ja) | 体脂肪の蓄積抑制または低減剤 | |
EP3892331A1 (en) | Composition for suppressing norovirus infection | |
JP7061560B2 (ja) | スフィンゴミエリン吸収促進用兼紅斑生成抑制用発酵乳ならびにその使用方法およびその製造方法、スフィンゴミエリンの吸収を促進させると共に紅斑の生成を抑制する方法、乳酸菌産生物およびスフィンゴミエリンを含有する発酵乳 | |
JP6849890B2 (ja) | デオキシリボ核酸保存用組成物およびその製造方法、デオキシリボ核酸を保存する方法、乳酸菌産生物およびその使用方法 | |
KR20200098224A (ko) | 청귤 추출박 또는 청피 유래의 다당을 포함하는 프리바이오틱스 및 이를 유효성분으로 포함하는 장내 프로바이오틱스 증식 촉진용 조성물 | |
KR102604295B1 (ko) | 생물전환된 쌍별귀뚜라미 발효물을 포함하는 식품조성물 및 이의 제조방법 | |
KR102657370B1 (ko) | 대두 단백질 분해능, 아미노산 생성능 개선 효과를 갖는 프로바이오틱스 조성물 | |
KR20240055598A (ko) | 신규 바실러스 벨레젠시스 균주 및 이의 용도 | |
KR20230014138A (ko) | 부티르산 생산능, 식이섬유 발효능 및 장 상피 방어벽 강화 효능을 가지는 로제부리아 인테스티날리스 균주 및 이의 용도 | |
NZ526544A (en) | Novel Probiotic Strain and Compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120125 |